Resources
3 Results (showing 1 - 3)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 11/18/2020 (updated 4/3/2024)
Healthcare provider burnout can lead to substance use disorder (SUD) and significant consequences for the individual, patients, and healthcare institutions. This webinar explored healthcare provider burnout, the scope of SUD in the medical community, and current pathways to recovery.
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.